The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity
出版年份 2013 全文链接
标题
The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity
作者
关键词
-
出版物
CANCER BIOLOGY & THERAPY
Volume 14, Issue 11, Pages 1032-1038
出版商
Informa UK Limited
发表日期
2013-10-05
DOI
10.4161/cbt.26106
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Characterization of the Human Folate Receptor Alpha Via Novel Antibody-Based Probes
- (2015) Daniel J. O’Shannessy et al. Oncotarget
- Folate Receptor Alpha Expression in Lung Cancer: Diagnostic and Prognostic Significance
- (2015) Daniel J. O'Shannessy et al. Oncotarget
- Antibody-Dependent Cell-Mediated Cytotoxicity Effector-Enhanced EphA2 Agonist Monoclonal Antibody Demonstrates Potent Activity against Human Tumors
- (2015) Elizabeth M. Bruckheimer et al. NEOPLASIA
- Crucial Role of Aspartic Acid at Position 265 in the CH2 Domain for Murine IgG2a and IgG2b Fc-Associated Effector Functions
- (2014) L. Baudino et al. JOURNAL OF IMMUNOLOGY
- Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer
- (2013) Deborah K. Armstrong et al. GYNECOLOGIC ONCOLOGY
- Expression of Folate Receptor-α (FRA) in Gynecologic Malignancies and its Relationship to the Tumor Type
- (2013) Daniel J. O’Shannessy et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
- (2013) James D Mellor et al. Journal of Hematology & Oncology
- Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy
- (2013) F V Negri et al. PHARMACOGENOMICS JOURNAL
- Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro
- (2012) B. A. Kamen et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies
- (2010) H. M. Horton et al. BLOOD
- Superior In vivo Efficacy of Afucosylated Trastuzumab in the Treatment of HER2-Amplified Breast Cancer
- (2010) Teemu T. Junttila et al. CANCER RESEARCH
- Farletuzumab, a Humanized Monoclonal Antibody against Folate Receptor , in Epithelial Ovarian Cancer: a Phase I Study
- (2010) J. A. Konner et al. CLINICAL CANCER RESEARCH
- Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia
- (2008) H. M. Horton et al. CANCER RESEARCH
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started